BFC
CTXR icon

Bedel Financial Consulting’s Citius Pharmaceuticals CTXR Stock Holding History

Bedel Financial Consulting’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 348
2022
Q1 		$0 Hold
1
– – ﹤0.01% 980
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1017
2021
Q3 		$0 Hold
1
– – ﹤0.01% 992
2021
Q2 		$0 Buy
+1
New +$60 ﹤0.01% 978

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bedel Financial Consulting's CTXR Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Citius Pharmaceuticals (CTXR) in Q2 2022, closing a stake of 1 share.

Bedel Financial Consulting first reported a position in CTXR in Q2 2021 and held it in 4 quarters. The position peaked at $0 in Q1 2022. 60 funds tracked by Wall St. Rank hold CTXR as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Citius Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 1 Citius Pharmaceuticals share in Q2 2022.
  • Bedel Financial Consulting first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Bedel Financial Consulting's Citius Pharmaceuticals position peaked at $0 in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.